On December 3, A+H pharmaceutical assets extended their correction, with the largest medical ETF (512170) and the only pharmaceutical ETF (562050) falling 0.58% and 0.19% respectively. Hong Kong innovative drug stocks showed greater volatility, with the HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880) dropping 1.43%.
In the A-share market, leading medical stocks mostly declined. WuXi AppTec fell 2.01%, while Aier Eye Hospital and Tigermed both lost over 1%. In contrast, Intco Medical and Snibe bucked the trend with gains. The medical ETF (512170) recorded two consecutive days of losses, hitting a four-month intraday low and closing below all moving averages.
Despite the downturn, bottom-fishing activity emerged. The ETF saw net inflows exceeding 114 million yuan during the decline, with 512170 showing premium trading volume of 495 million yuan, indicating strong buying interest.
The A-share pharmaceutical sector demonstrated relative resilience, with the pharmaceutical ETF (562050) outperforming the broader market. Traditional Chinese medicine leaders contributed significantly, with Pien Tze Huang rising 1.33% and Yunnan Baiyao gaining 0.6%. Innovative drug stocks diverged, with Yifan Pharmaceutical surging 6.11% against the trend, while heavyweight BeiGene declined 1.59%.
As the only ETF tracking the CSI Pharmaceutical Index, 562050 maintains about 25% weighting in traditional Chinese medicine alongside innovative drug holdings. The TCM sector's high dividend yield and stable performance help mitigate the volatility of innovative drugs, reducing overall index fluctuations.
Hong Kong's innovative drug sector exhibited high volatility, with 520880 extending losses for four consecutive days. The ETF swung 2.5% intraday with 211 million yuan turnover, as top holdings including BeiGene, Innovent Biologics, Sino Biopharmaceutical, Akeso, and CSPC Pharmaceutical all closed lower.
Notably, 520880 maintained a wide premium throughout the session, signaling particularly strong buying interest. Analysts suggest innovative drugs could become a major driver of year-end rallies, considering industry growth expectations through 2026.
The A+H pharmaceutical sector has been adjusting since early September, with nearly three months of correction. Analysts note that while innovative drug risks from previous highs have largely dissipated, valuations in medical sectors have further compressed, potentially creating favorable long-term entry points.
Industry observers emphasize that pharmaceutical demand remains fundamentally strong, driven by unmet medical needs and sustained R&D investment. China has emerged as a key player in global innovative drug development, with overseas licensing activity continuing to grow annually.
For allocation strategies, analysts recommend maintaining balanced sector exposure while monitoring improving fundamentals across the innovative drug supply chain. Traditional Chinese medicine and medical devices may also warrant attention as recovery prospects emerge.
Investors are reminded that recent market volatility may persist, with short-term performance not necessarily indicative of future trends. Careful consideration of individual risk tolerance and position management remains crucial.
Risk disclosures note that various ETFs track different underlying indices with varying inception dates. Constituent stock mentions are for illustrative purposes only and do not constitute investment recommendations. Fund managers classify 520880 and medical ETF feeder funds as R4 (medium-high risk) products suitable for aggressive investors (C4+), while 512170 and 562050 are rated R3 (medium risk) for balanced investors (C3+). Past performance does not guarantee future results, and investment decisions carry inherent risks.
Comments